Monographie - Oxaliplatin

Last update :
08/05/2024

Oxaliplatin

Chemical structure

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	Germany
Bendaplatin	Germany
Bioezulen	Brazil
Celdach	Peru
Crisapla	Chile, Ecuador, Venezuela
Crisatinox	Turkey
Dabenzol	Argentina, Ecuador
Dacplat	Argentina
Eloxarin	Ecuador
Eloxatin	Austria, Belgium, Brazil, Chile, Colombia, Egypt, Great Britain, Iran, Italy, Luxembourg, Malaysia, Mexico, New Zealand, Norway, Peru, Portugal, Romania, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United States of America, Venezuela
Eloxatine	France, Morocco, Switzerland
Entia	Colombia, Mexico
Euroxaliplatine	Germany
Glenoxal	Peru
Goxyral	Argentina, Ecuador
Kebir	Argentina, Peru
Linoxa	Turkey
Lisix	Chile
Metaplatin	Argentina
Oliptino	Argentina
Onicol	Chile, Peru
Oxalibbs	Brazil
Oxaliplan	Germany
Riboxatin	Germany

References : Oxaliplatin

	Type	Publication
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Journal	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Journal	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Journal	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Journal	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Manufacturer	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Manufacturer	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Journal	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Journal	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Journal	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Manufacturer	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Journal	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Manufacturer	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Manufacturer	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Journal	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Journal	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Journal	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales